Vtv Therapeutics Stock Signals

Healthcare > Biotechnology

Buy 5VT

*Your capital is at risk

0.85€

-0.0050 (-0.588%)

At Close: May 19, 2023

Latest Data & Signals Issued

Below are some of the latest signals issued for vTv Therapeutics Inc.

General

	Signal Type	Signal Value	Data
	Score	0.000	335 days ( -36.84 %
	Last Price	0.85€	-0.588 %
Performance History 7 Days 0.80€ 0.85€ 5.62% 30 Days 0.700€ 0.85€ 20.71% 12 Mos 0.357€ 0.85€ 136.89%

5/18

Active Buy Signals

Premium Feature

Specific Signals

Short Term

Net score: 23.72

Signal Type	Signal Value	Importance	Data
High / Low	Buy	Very Low	0.85€ - 0.85€ Position: 0% from low / 100.00% from high · Momentum: 3.24%
Trend - 3 mos	-2.33 %	High	Width: 37.08 %
Pred. range - 3 mos	0.622€ - 0.85€	Low	-26.43 % - 0.85 %
Volume Direction	Sell	High	Volume: 1 · Direction: 0
Pivot Short	Sell	Very Low	May 18, 2023 - 2 days
RSI Short Pivot Signal	Sell	Very Low	May 18, 2023 - 2 days
Short MA 3 mos	Sell	Low	May 12, 2023 - 6 days
Long MA 3 mos	Sell	Medium	May 05, 2023 - 11 days
Short/Long MA 3 mos	Buy	Medium	May 08, 2023 - 10 days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now

Long Term

Net score: 46.06

Signal Type	Signal Value	Importance	Data
Trend - 12 mos	-5.66 %	Very High	Width: 310.64 %
Pred. range - 12 mos	0.290€ - 1.19€	High	-65.66 % - 41.01 %
Short MA 12 mos	Sell	Very High	May 05, 2023 - 11 days
Long MA 12 mos	Buy	Very High	May 08, 2023 - 10 days
Short/Long MA 12 mos	Buy	Very High	May 16, 2023 - 4 days
Pivot Long	Sell	Low	May 18, 2023 - 2 days
RSI Long Pivot Signal	Sell	Low	May 18, 2023 - 2 days
Bollinger	Sell	Medium	Nov 30, -0001 - N/A days
MACD	Buy	High	No Dates Stored For This Signal

Notice: Technical analysis is hidden due to insufficient data.

There can be multiple reasons for our algorithm to not provide conclusion. One of them can be low or no liquidity.

If you think this is not correct, please

ABOUT VTV THERAPEUTICS INC.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is a...

Read Full Profile Here